Top Story Today
The Three-Headed Antibody Gunning for Cancers That Ignore Immunotherapy
Akeso just received clinical trial approval from China's NMPA for AK150, a trispecific antibody that simultaneously blocks three immune-suppressive proteins (ILT2, ILT4, and CSF1R) in a single molecule. It's the only drug in the world targeting all three at once. The goal: turn "cold" tumors, the ones that shrug off checkpoint inhibitors, into targets the immune system can actually see. Animal models showed dose-dependent tumor shrinkage across every group tested. Building a three-headed antibody is exponentially harder than making a bispecific, but Akeso already has seven drugs on the market and 15 multispecific candidates in trials. Over 50 trispecifics are now in clinical development globally; none have been approved yet.
Why it matters: If trispecific antibodies work in humans, they won't just validate one drug. They'll open an entirely new class of engineered therapeutics for the cancers that have resisted every prior generation of immunotherapy.
Read more →Funding and Financings
AI Drug Designer Generate:Biomedicines Prices the Biggest Biotech IPO of 2026, Then Drops on Day One
Generate Biomedicines raised $400 million at $16 per share, making it 2026's largest biotech IPO. Its AI platform designs proteins from scratch, and its lead asthma drug has reached Phase 3. Amgen and Novartis have both paid for platform access. The stock fell 6% on day one, opening at $15, a reminder that clinical-stage biotechs need clinical proof to hold up.
Read more →Eikon Therapeutics Raises $381M on a Platform That Literally Watches Proteins Move
Nobel laureate Eric Betzig's company pulled off the largest biotech IPO in two years by building microscopes that track individual proteins inside living cells. Led by former Merck R&D chief Roger Perlmutter, Eikon has a cancer pipeline anchored by a Phase 2/3 melanoma trial combining its lead drug with Keytruda. The company now sits on over $1.1 billion in total capital raised.
Read more →Clinical and Regulatory
One Patient's Forearm Has Been Making Insulin for 14 Months, No Immune Drugs Required
Sana Biotechnology's engineered islet cells, injected into a single Type 1 diabetes patient's forearm with zero immunosuppression, are still alive and producing insulin at 14 months. C-peptide levels (the marker showing your body makes its own insulin) actually rose between months 12 and 14. It's one patient at a sub-therapeutic dose, but the implications are enormous: if this scales, it could leapfrog Vertex's approach, which requires lifelong immune-suppressing drugs.
Read more →J&J's Nipocalimab Scores Fifth FDA Fast Track, This Time for Lupus
Nipocalimab earned Fast Track designation for systemic lupus after its Phase 2b JASMINE trial hit its primary endpoint in 228 patients, becoming the first positive study of an FcRn blocker in SLE. The drug works by blocking the receptor that recycles harmful autoantibodies, and it showed steroid-sparing potential. J&J is now enrolling the Phase 3 GARDENIA study, which will determine whether lupus patients finally get a way out of the steroid trap.
Read more →FDA Watch
The FDA Just Made Biosimilar Development Up to $20 Million Cheaper Per Program
New draft guidance lets biosimilar developers use non-U.S. comparator products in pharmacokinetic studies, eliminating expensive three-way trials. Combined with October 2025 reforms that eliminated comparative clinical efficacy studies and switching study requirements, total biosimilar development costs could drop from $100-200 million to roughly $80-100 million. The biggest winners: smaller developers previously priced out; the biggest losers: originator biologics companies watching their patent cliffs get steeper.
Read more →First-Ever Drug Approved for Arginase 1 Deficiency, a Disease Affecting ~250 Americans
Loargys (pegzilarginase) is now the first targeted therapy for ARG1-D, an ultra-rare metabolic disorder where toxic arginine buildup slowly damages the brain. In the PEACE trial, treated patients saw a 76% drop in plasma arginine, with over 90% achieving plasma arginine below 200 μmol/L versus zero on placebo. It's an accelerated approval, so long-term neurological confirmation is still required by 2034.
Read more →FDA Approves Bysanti for Schizophrenia and Bipolar I, but There's a Catch
Vanda Pharmaceuticals' new antipsychotic Bysanti (milsaperidone) won FDA approval, but your body rapidly converts it back into iloperidone, the active ingredient in Vanda's older drug Fanapt. It's a lifecycle strategy wrapped in a new chemical entity, complete with patent protection through 2044. Vanda's stock jumped 33-44% on the news, though analysts project only modest sales of about $100 million by 2033.
Read more →